Journal of translational medicine · 2025
Single-cell RNA sequencing reveals the adverse role of cDC3s in the response of ulcerative colitis patients to anti-TNF-α therapy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Zhangqin, Ma Ruijie, Nie Zhongshun, Ren Youxu, Li Yunxing, Miao Yinglei, Jia Jie, Miao Jiarong
Аннотация
BACKGROUND: Ulcerative colitis (UC) is a chronic nonspecific inflammatory disease that belongs to the inflammatory bowel disease (IBD). The complex etiology of UC contributes to heterogeneous clinical outcomes in treatment. In clinical practice, approximately 30% of UC patients do not respond to first-line treatment with anti-TNF-α therapy.
METHODS: In this study, we performed single-cell sequencing of intestinal mucosal tissue before (pre) and after (post) anti-TNF-α therapy in UC patients and analyzed it in relation to therapy response (-R) and non-response (-NR).
RESULTS: We found that immune cell profiles differed between the pre-R and post-R groups. Specifically, the proportion of type 3 conventional dendritic cells (cDC3s) with distinct transcriptomes was lower in the post-R group than in the pre-R group and was not different between the pre-NR and post-NR groups. Cell trajectory analysis revealed that the number of cells differentiated into cDC3s significantly decreased in the post-R group, and the genes related to the MAPK signaling pathway obviously increased in these cells. Additionally, the interaction analysis of ligands and receptors revealed that the interactions between HLA-DPA1/DPB1 in fibroblasts and TNFSF9 in cDC3s and between CD44 in fibroblasts and TYROBP in cDC3s were significantly weakened in the post-R group compared to the pre-R group.
CONCLUSION: We provide a comprehensive resource detailing the dynamic changes in immune cells during TNF-α therapy in UC patients and identify the reduction in the number of functionally distinct cDC3s as a potential biomarker for predicting anti-TNF-α therapy outcomes.
METHODS: In this study, we performed single-cell sequencing of intestinal mucosal tissue before (pre) and after (post) anti-TNF-α therapy in UC patients and analyzed it in relation to therapy response (-R) and non-response (-NR).
RESULTS: We found that immune cell profiles differed between the pre-R and post-R groups. Specifically, the proportion of type 3 conventional dendritic cells (cDC3s) with distinct transcriptomes was lower in the post-R group than in the pre-R group and was not different between the pre-NR and post-NR groups. Cell trajectory analysis revealed that the number of cells differentiated into cDC3s significantly decreased in the post-R group, and the genes related to the MAPK signaling pathway obviously increased in these cells. Additionally, the interaction analysis of ligands and receptors revealed that the interactions between HLA-DPA1/DPB1 in fibroblasts and TNFSF9 in cDC3s and between CD44 in fibroblasts and TYROBP in cDC3s were significantly weakened in the post-R group compared to the pre-R group.
CONCLUSION: We provide a comprehensive resource detailing the dynamic changes in immune cells during TNF-α therapy in UC patients and identify the reduction in the number of functionally distinct cDC3s as a potential biomarker for predicting anti-TNF-α therapy outcomes.